查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495979

全球甲状腺功能检测市场 - 2024 年至 2029 年预测

Global Thyroid Function Test Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

甲状腺功能检测市场预计到2029年将达到2,414,733,000美元，复合年增长率为5.40%。 2022年市场规模为1,671,171,000美元。

人体的甲状腺会分泌重要的激素，大大影响人体的生长、发育和正常健康。荷尔蒙分泌的增加或减少会导致健康状况。因此，诊断和管理对于检测人体内的甲状腺激素至关重要。

预测期内推动甲状腺功能检测市场的关键原因是甲状腺激素日益失衡及其对健康和身体的不利影响。健康意识的提高和医疗保健支出也正在扩大市场范围。此外，增加对医疗领域的投资以及鼓励早期发现疾病并及时用药以增加生存机会预计将支持市场成长。

市场驱动因素：

  • 甲状腺激素功能障碍的发生频率不断增加，推动了定期监测甲状腺功能的需求，并推动了市场的成长。

甲状腺激素功能障碍是预计在预测期内推动甲状腺功能测试市场需求的另一个关键因素。透过控制燃烧卡路里的能力，甲状腺激素会影响身体的新陈代谢。当甲状腺激素水平过高或过低时，甲状腺激素会改变身体形状，分别使人变瘦或变胖。由于生活方式的复杂性，甲状腺激素问题的案例数量不断增加，预计将促使定期检查，以获得更好的医疗照护。

据美国甲状腺协会称，超过 12% 的美国一生中至少患有一次甲状腺功能障碍。超过 2000 万人患有甲状腺问题，其中 60% 的人不知道自己的病情。身体意识、令人信服的激励措施以及持续、及时的身体检查的机构后续行动预计将在未来推动一个巨大的表面市场。

  • 肥胖症的日益普及正在引起严重关注，预计将为甲状腺功能检测行业提供巨大的市场前景。

导致这现象显着成长的另一个因素是世界人口日益肥胖。世界卫生组织 (WHO) 表示，过去 40 年来，肥胖率增加了两倍。因此，到 2022 年，将有 25 亿成年人超重，8.9 亿人患有肥胖症。此外，到 2022 年，将有 3,700 万名 5 岁以下儿童和 3.9 亿 5 岁至 19 岁男孩和女孩超重或肥胖。

肥胖率的稳定上升引起了严重关注，甲状腺激素检测预计会增加，以实现更好的收益和监管。此外，甲状腺癌等甲状腺相关疾病的增加预计将在预测期内推动市场。

  • 甲状腺癌发病率的上升预计将推动市场扩张。

促进甲状腺功能检测的因素之一是甲状腺癌病例的增加。值得注意。甲状腺疾病的早期诊断是必要的，接受治疗时定期监测也很重要。此外，甲状腺癌的特殊病例增加了对甲状腺功能检查的需求。此外，技术进步和世界人口老化可能会进一步增加市场需求。甲状腺癌一词是指异常细胞从正常甲状腺出现并生长成肿瘤的过程。

根据Cancer.net报道，美国新增一例甲状腺癌病例。此外，在美国，女性病例数每年以 2% 的速度增加。日益增加的癌症威胁可能为甲状腺功能测试提供一个稳定的市场。

市场限制因素：

  • 有关甲状腺功能测试的资讯有限可能会限制甲状腺功能测试市场的成长。

每次甲状腺功能测试的主要障碍之一是资讯有限或无法知道测试的阳性结果。根据 ATA资料，由于对甲状腺领域缺乏认识或兴趣，60% 的美国人不知道自己的甲状腺状况。

  • 检测成本的增加可能会阻碍甲状腺功能检测市场的成长。

虽然常见的甲状腺功能测试是可以负担的，但基因测试和放射性碘摄取扫描等更复杂的测试的费用可能会很昂贵。这可能会限制某些特定患者的机会。

主要进展：

  • 2023 年 2 月 - Parkway Laboratories 的新测试资料「妊娠期甲状腺筛检」（代码：TSP）已新增至产品组合。
  • 2023 年 1 月 - Cipla 推出 Cippoint。经过 CE IVD 认证的 POCT 设备为医疗专业人员提供了一种针对许多非传染性疾病和感染疾病的便捷的就地检验设备。它有心臟、糖尿病、不孕症、甲状腺功能、发炎、代谢标记、凝血标记等多种参数。 Cipla 是印度开发的诊断工具，透过以合理的价格提供使用萤光的准确测试而赢得了信任。自动化系统（Cippoint）为医疗专业人员提供即时结果（2-15 分钟）并简化临床决策流程。
  • 2022 年 10 月 - 一项 Frontier 研究发现，女性肥胖时 TSH 水平会升高，而瘦素水平是甲状腺功能参数的关键代谢决定因素。在一大群肥胖的甲状腺功能减退患者中，不同 BMI 范围内的 TSH 和 fT4 水平模式表明，下丘脑-垂体-甲状腺轴与体重之间存在多效性关联。
  • 2022 年 1 月 - Quest Diagnostics 推出 QuestDirect(TM)，这是一项针对成人健康管理的线上预防性健康服务。它包括诊断工具、重要资讯筛检和健康风险评估。该服务包括诊断工具、生物识别筛检和健康风险评估，定位为健康教育报告、健康提示以及与医生一对一的虚拟咨询。创建该服务的目的是让用户能够存取个人健康资讯和预防保健，并且可以根据每位客户的繁忙日程安排在方便的时间。

主要市场区隔：

按类型

  • 甲状腺刺激素测试
  • T4测试
  • T3测试
  • 其他的

按指示

  • 甲状腺机能低下症
  • 甲状腺功能亢进症
  • 甲状腺癌
  • 其他的

按最终用户

  • 医院和诊所
  • 诊断中心
  • 其他的

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 英国
  • 德国
  • 西班牙
  • 法国
  • 其他的
  • 中东/非洲中东/非洲
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 其他的
  • 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 台湾
  • 泰国
  • 印尼
  • 其他的

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行概述

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章甲状腺功能测试的全球市场：按类型

  • 介绍
  • 甲状腺刺激素测试
  • T4测试
  • T3测试
  • 其他的

第六章 甲状腺功能检测的全球市场：依适应症分类

  • 介绍
  • 甲状腺机能低下症
  • 甲状腺功能亢进症
  • 甲状腺癌
  • 其他的

第七章甲状腺功能测试的全球市场：依最终用户分类

  • 介绍
  • 医院和诊所
  • 诊断中心
  • 其他的

第八章甲状腺功能测试的全球市场：按地区

  • 介绍
  • 北美洲
  • 南美洲
  • 欧洲
  • 中东/非洲
  • 亚太地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Abbott
  • Randox Laboratories Ltd
  • bioMerieux SA
  • Thermo Fisher
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers
  • Qualigen Inc.
  • Beckman Coulter, Inc.
  • Quidel Corporation
简介目录
Product Code: KSI061611918

The global thyroid function test market is expected to reach a value of US$2,414.733 million by 2029, growing at a CAGR of 5.40%. It was valued at US$1,671.171 million in 2022.

The thyroid gland in the human body secretes important hormones that are great determinants of the human body's growth, development, and proper health. Any increased or decreased production of the hormone can cause a disease condition. Therefore, diagnosis and management are essential in inspecting the thyroid hormones in the human body.

The prime reason driving the market for thyroid function tests during the forecasted period is the rising thyroid hormone imbalance and its adverse effect on health and the body. Surging health consciousness and healthcare expenditure also increase the scope of the market. Furthermore, increasing investment in the healthcare sector and encouraging early detection of disease for timely medication for better chances of survival are projected to support the market growth.

Market Drivers:

  • The Growing frequency of thyroid hormone dysfunction has promoted the need for regular monitoring of thyroid function is driving the market growth.

Thyroid hormone dysfunction is another key factor anticipated to fuel the market demand for thyroid function tests in the projected time frame. By controlling the calorie-burning capability, the thyroid hormone influences the metabolism of the body. It alters the shape of the body when its levels are too high or too low, making a person lean or fat, respectively. Increasing instances of thyroid hormone issues owing to lifestyle complexities are expected to encourage periodic testing for better healthcare.

According to the American Thyroid Association, in the US, over 12% of the population suffer from thyroid malfunction at least once in their lives. More than 20 million people have thyroid issues, and 60% are unaware of their states. Awareness in terms of the body and persuasive motivation and follow from agencies for consistent timely body checks are anticipated to propel the substantial apparent market in the future.

  • Rising obesity has raised serious concerns, which are expected to provide significant market prospects for the thyroid function test industry.

Another factor that will contribute significantly to the tremendous growth is the increasing obesity in the worldwide population. The World Health Organization figures out that the overweight rate has tripled in the last 40 years. Consequently, in 2022 the number of overweight adults was 2.5 billion, and 890 million were living with obesity. Moreover, in 2022, 37 million children less than five years old and also 390 million boys and girls between the ages of 5 and 19 years old were overweight or obese.

The robust growing obesity rates have raised serious concerns, which are anticipated to increase thyroid hormone testing for better monetization and regulation. In addition, the increased number of diseases associated with the thyroid such as thyroidal cancer is expected to drive the market within the forecasted period.

  • The rising incidence of thyroid cancer is projected to drive market expansion.

One of the drivers of thyroid function tests includes the growth of thyroid cancer cases. Notably. Thyroid disorders require early diagnosis, while regular monitoring is essential when seeking treatment. In addition, due to exceptional cases of cancer of the thyroid glands the demand for testing of thyroid function is increasing. Also, technological improvements and an aging global population may further increase market demand. The term thyroid cancer refers to the process by which abnormal cells emerge from a normal thyroid gland and the growth of tumors.

According to Cancer.net, the United States of America recorded new cases of thyroid cancer. Furthermore, according to the report, the US has been reporting an increasing number of women cases at a rate of 2% annually. The increasing cancer threat will provide a stable market for thyroid function tests.

Market Restraint:

  • Limited information about thyroid function tests could curb the thyroid function test market growth.

The one of the main obstacles with respective thyroid function tests is limited information or not being able to know the positive output from the test. Data from ATA states that 60% of Americans are unaware of their thyroid condition owing to a lack of awareness and interest in the sector, which reduces potential patient tests and hence hinders' market growth.

  • Increased cost for testing can hinder the thyroid function test market growth

While the price of the general tests of thyroid function is affordable, the cost of the more complex tests like genetic testing and radioactive iodine uptake scans may be high. This might lead to the restriction of opportunities for some particular patients.

Key Developments:

  • February 2023- Thyroid Screen in Pregnancy (code: TSP), a new test profile from Parkway Laboratories, added to the portfolio. With a trimester-specific reference period, the new test profile's components are identical to those of the thyroid screen basic profile.
  • January 2023- Cipla launched Cippoint, a CE IVD-accredited POCT device that provides healthcare professionals with a handy point-of-care testing device for many non-contagious diseases and infections. It has many parameters to rule the cardiac, diabetes, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. Cipla, developed in India, is a diagnostic tool that is trusted for its precise tests at a reasonable cost utilizing the immunofluorescence technique. Its automated system ( Cippoint ) provides an immediate result for Healthcare professionals (2-15 minutes) and smooths the way of clinical decision-making process. The network server is optimized to cater to regions with low connections such as rural, mobile, and remote areas.
  • October 2022- Frontier study found that TSH levels increase with obesity in females, with leptin levels being the main metabolic determinant of thyroid function parameters. The pattern of TSH and fT4 levels across different BMI ranges in a large cohort of euthyroid patients with obesity suggests a multifold association between the hypothalamic-pituitary-thyroid axis and body weight. However, the potential mechanisms are incompletely understood, and the small proportion of individuals with obesity in published cohort studies provide limited insights into metabolic correlates of thyroid function in obesity.
  • January 2022- Quest Diagnostics began an online preventive care service called QuestDirect(TM) in collaboration with adults as a way for them to take over their health. The service comprises diagnostic tools, biometric screening, and health risk assessment. It, too, ranks as an educational report on health, including some health tips, and puts forward a one-on-one virtual consultation with a physician. This service is created to ensure users have access to personal health information and preventive care that can be scheduled at a convenient time for each client considering their busy schedules.

Key Market Segments:

By Type

  • Thyroid Stimulating Hormone Test
  • T4 Tests
  • T3 Tests
  • Others

By Indication

  • Hypothyroidism
  • Hyperthyroidism
  • Thyroid Cancer
  • Others

By End Users

  • Hospitals and clinics
  • Diagnostic centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • Spain
  • France
  • Others
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL THYROID FUNCTION TEST MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Thyroid Stimulating Hormone Test
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. T4 Tests
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. T3 Tests
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Others
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL THYROID FUNCTION TEST MARKET BY INDICATION

  • 6.1. Introduction
  • 6.2. Hypothyroidism
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Hyperthyroidism
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Thyroid Cancer
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Others
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness

7. GLOBAL THYROID FUNCTION TEST MARKET BY END USERS

  • 7.1. Introduction
  • 7.2. Hospitals and clinics
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Diagnostic centers
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Others
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL THYROID FUNCTION TEST MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Indication
    • 8.2.3. By End Users
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Indication
    • 8.3.3. By End Users
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Indication
    • 8.4.3. By End Users
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. Spain
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. France
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Indication
    • 8.5.3. By End Users
    • 8.5.4. By Country
      • 8.5.4.1. UAE
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. Saudi Arabia
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Indication
    • 8.6.3. By End Users
    • 8.6.4. By Country
      • 8.6.4.1. Japan
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. China
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Abbott
  • 10.2. Randox Laboratories Ltd
  • 10.3. bioMerieux SA
  • 10.4. Thermo Fisher
  • 10.5. DiaSorin S.p.A.
  • 10.6. F. Hoffmann-La Roche Ltd.
  • 10.7. Siemens Healthineers
  • 10.8. Qualigen Inc.
  • 10.9. Beckman Coulter, Inc.
  • 10.10. Quidel Corporation